Zelluna ASA
Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company has a clinical partnership with Medpace Holdings, Inc. to support the clinical trial of ZI-MA4-1 (ZIMA-101); and collaboration with Etcembly Ltd for AI-enabled TCR engineering. The company was founded in 2016 and is based in Oslo, Norway.
Market Cap & Net Worth: Zelluna ASA (ZLNA)
Zelluna ASA (OL:ZLNA) has a market capitalization of $46.11 Million (Nkr525.40 Million) as of March 18, 2026. Listed on the OL stock exchange, this Norway-based company holds position #25575 globally and #142 in its home market, demonstrating a 23.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zelluna ASA's stock price Nkr20.00 by its total outstanding shares 26269801 (26.27 Million).
Zelluna ASA Market Cap History: 2025 to 2026
Zelluna ASA's market capitalization history from 2025 to 2026. Data shows growth from $31.82 Million to $46.11 Million (0.00% CAGR).
Zelluna ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zelluna ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ZLNA by Market Capitalization
Companies near Zelluna ASA in the global market cap rankings as of March 18, 2026.
Key companies related to Zelluna ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Zelluna ASA Historical Marketcap From 2025 to 2026
Between 2025 and today, Zelluna ASA's market cap moved from $31.82 Million to $ 46.11 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr46.11 Million | +44.93% |
| 2025 | Nkr31.82 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Zelluna ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.11 Million USD |
| MoneyControl | $46.11 Million USD |
| MarketWatch | $46.11 Million USD |
| marketcap.company | $46.11 Million USD |
| Reuters | $46.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.